HTG Molecular Diagnostics, Inc.
Simbols: HTGM
NASDAQ
0.48
USDTirgus cena šodien
-0.0745
P/E koeficients
-0.0008
PEG koeficients
1.06M
MRK Cap
- 0.00%
DIV ienesīgums
HTG Molecular Diagnostics, Inc. (HTGM) Finanšu pārskati
Bilance
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 39.4 | 12.2 | 21.9 | 28.7 | |||||||||||
balance-sheet.row.short-term-investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.net-receivables | 4.77 | 1.4 | 2.1 | 1.6 | |||||||||||
balance-sheet.row.inventory | 5.21 | 0.9 | 2 | 1.5 | |||||||||||
balance-sheet.row.other-current-assets | 4.89 | 1.1 | 1.2 | 1.1 | |||||||||||
balance-sheet.row.total-current-assets | 54.94 | 15.7 | 27.2 | 32.9 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 6.65 | 1.6 | 2.5 | 2.2 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 2.88 | 0.5 | 0.8 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 9.52 | 2.1 | 3.3 | 2.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.account-payables | 4.08 | 1.2 | 1.6 | 1.3 | |||||||||||
balance-sheet.row.short-term-debt | 19.02 | 4.3 | 5.6 | 3.7 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 4.92 | 0.5 | 6.1 | 8.9 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 8.71 | 2.8 | 2.6 | 2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 20.01 | 4.1 | 10.1 | 13.5 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 3.41 | 1 | 1.4 | 1.1 | |||||||||||
balance-sheet.row.total-liab | 51.81 | 12.4 | 20.1 | 20.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -910.86 | -229.9 | -208.3 | -191.2 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.02 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 923.5 | 235.3 | 218.7 | 205.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 64.46 | - | - | - | |||||||||||
Total Investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.total-debt | 23.94 | 4.8 | 11.7 | 12.6 | |||||||||||
balance-sheet.row.net-debt | -0.24 | -7.4 | 2.1 | -9.8 |
Naudas plūsmas pārskats
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.49 | 0.6 | 0.7 | 1.3 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -1.4 | 0.7 | |||||||||||
cash-flows.row.stock-based-compensation | 0.68 | 0.8 | 1.4 | 1.8 | |||||||||||
cash-flows.row.change-in-working-capital | -0.16 | -0.1 | -1 | -0.2 | |||||||||||
cash-flows.row.account-receivables | -0.38 | 0.7 | -0.8 | 1.6 | |||||||||||
cash-flows.row.inventory | 0.27 | 0.1 | -1.4 | -0.3 | |||||||||||
cash-flows.row.account-payables | -0.2 | -0.5 | 0.5 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0.16 | -0.4 | 0.7 | -1.5 | |||||||||||
cash-flows.row.other-non-cash-items | 2.31 | 1.9 | 0.9 | 0.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -16.83 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.acquisitions-net | -99828.51 | 0 | -25018 | -72.5 | |||||||||||
cash-flows.row.purchases-of-investments | -11.15 | -7.6 | -18.6 | -12.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 14.52 | 19.9 | 12.6 | 31.6 | |||||||||||
cash-flows.row.other-investing-activites | 99828.64 | 0.1 | 25018 | 72.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 3.48 | 12.4 | -6.7 | 18.7 | |||||||||||
cash-flows.row.debt-repayment | -7.16 | -7.8 | -0.8 | -3.6 | |||||||||||
cash-flows.row.common-stock-issued | 2.8 | 1.4 | 10.7 | 7.5 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 6.09 | 15 | 0.5 | 5.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1.73 | 8.6 | 10.4 | 9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -11.62 | 2.6 | -12.8 | 11.5 | |||||||||||
cash-flows.row.cash-at-end-of-period | 24.18 | 12.2 | 9.6 | 22.4 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 35.79 | 9.6 | 22.4 | 10.9 | |||||||||||
cash-flows.row.operating-cash-flow | -16.83 | -18.4 | -16.5 | -16.3 | |||||||||||
cash-flows.row.capital-expenditure | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.free-cash-flow | -16.85 | -18.4 | -17.2 | -16.7 |
Peļņas vai zaudējumu aprēķina rinda
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6.21 | 6.4 | 8.9 | 8.5 | |||||||||||
income-statement-row.row.cost-of-revenue | 4.87 | 4.6 | 4.1 | 4 | |||||||||||
income-statement-row.row.gross-profit | 1.35 | 1.8 | 4.8 | 4.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 6.47 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 20.94 | 22.6 | 22.6 | 24.1 | |||||||||||
income-statement-row.row.cost-and-expenses | 25.8 | 27.2 | 26.7 | 28.1 | |||||||||||
income-statement-row.row.interest-income | 0.19 | 0.1 | 0 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.55 | 0.7 | -1.7 | 1.6 | |||||||||||
income-statement-row.row.ebitda-caps | -19.29 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -19.59 | -20.8 | -17.8 | -19.6 | |||||||||||
income-statement-row.row.income-before-tax | -20.14 | -21.6 | -17.1 | -20.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0.01 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 |
Biežāk uzdotie jautājumi
Kas ir HTG Molecular Diagnostics, Inc. (HTGM) kopējie aktīvi?
HTG Molecular Diagnostics, Inc. (HTGM) kopējie aktīvi ir 17777655.000.
Kādi ir uzņēmuma gada ieņēmumi?
Gada ieņēmumi ir 3471815.000.
Kāda ir uzņēmuma peļņas norma?
Uzņēmuma peļņas norma ir 0.184.
Kāda ir uzņēmuma brīvā naudas plūsma?
Brīvā naudas plūsma ir -4.967.
Kāda ir uzņēmuma neto peļņas norma?
Neto peļņas norma ir -3.020.
Kādi ir uzņēmuma kopējie ieņēmumi?
Kopējie ieņēmumi ir -2.946.
Kāda ir HTG Molecular Diagnostics, Inc. (HTGM) tīrā peļņa (tīrie ienākumi)?
Tīrā peļņa (tīrie ienākumi) ir -21594476.000.
Kāds ir uzņēmuma kopējais parāds?
Kopējais parāds ir 4833948.000.
Kāds ir pamatdarbības izdevumu skaits?
Darbības izdevumi ir 22623682.000.
Kāds ir uzņēmuma skaidrās naudas rādītājs?
Uzņēmuma nauda ir 2996409.000.